ABSTRACT
606 Figure 2Pathways of differentially expressed genes associated with high HERVs/LINEs expression per cell type in 120 SLE patients.[Figure omitted. See PDF] 606 Table 1HERVs/LINEs expression associated with clinical outcomes, adjusted for sex, race and immunosuppressive medication use in 120 SLE participants. (FDR p<0.05) HERVs/LINEs counts CD4 CD14 CD19 NK Up Down Up Down Up Down Up Down Anti Sm antibody production 5 8 5 7 21 27 2 7 Disease severity(severe 2 cluster vs mild cluster) 2 15 4 10 1087 44 461 0 History of renal disease 1 4 2 1 5 12 0 0 Anti-RNP antibody production 6 7 4 8 17 9 1 0 Anti-dsDNA antibody production 35 2 5 2 21 11 0 0 Disease activity (SLEDAI score) 1 15 2 13 2 227 0 1 Con ress, date, location Lupus 21st Century, September 20, 2022 – September 23, 2022, Loews Ventana Canyon Resort Congress website https://web.cvent.com/event/a6cd0d72-4b4e-40a4-939b- c133c05df3af/summary guidelines https://web.cvent.com/event/a6cd0d72-4b4e-40a4-939b- c133c05df3af/websitePage:795426fe-0fc9-44d7-9156-b30723c39052 Submission category • Genetics• Nucleic Acids in SLE• The Macrophage in SLE• Lupus Nephritis• Brain Injury in SLE• Pharmacoepidemiology• Clinical Research in SLE• Covid-19• Cutaneous SLE• SLE Diagnosis• Lupus-Targeted Therapeutics• Cardiovascular Disease and Lupus• PROs• Biomarkers in Clinical Trials• B Cells• Transcriptomics• T Cells• Innate Immunity• Autoantibodies• Microbiome Presentation preference N/A Character/word limit No limit stated, will ask congress to confirm Figures/tables Allowed- No limit stated, will ask congressEmbed in word doc References N/A Style Other points A lay summary is required – see separate Lay summary file Disclosures Not needed at submission Other Submission deadline August 1, 2022 at 11:59 PM ET